Abstract:Summary Background COVID-19-associated pulmonary aspergillosis (CAPA) has been reported to be an emerging and potentially fatal complication of severe COVID-19. However, risk factors for CAPA have not been systematically addressed to date. Methods In this systematic review and meta-analysis to identify factors associated with CAPA, we comprehensively searched five medical databases: Ovid MEDLINE; Ovid Embase; the Cochrane Database of Systematic Reviews; the Cochrane Central Register of Controlled Trials; and the WHO COVID-19 Database. All case-control and cohort studies in adults (aged >18 years) that described at least six cases of CAPA and evaluated any risk factors for CAPA, published from Dec 1, 2019, to July 27, 2023, were screened and assessed for inclusion. Only studies with a control population of COVID-19-positive individuals without aspergillosis were included. Two reviewers independently screened search results and extracted outcome data as summary estimates from eligible studies. The primary outcome was to identify the factors associated with CAPA. Meta-analysis was done with random-effects models, with use of the Mantel–Haenszel method to assess dichotomous outcomes as potential risk factors, or the inverse variance method to assess continuous variables for potential association with CAPA. Publication bias was assessed with funnel plots for factors associated with CAPA. The study is registered with PROSPERO, CRD42022334405. Findings Of 3561 records identified, 27 articles were included in the meta-analysis. 6848 patients with COVID-19 were included, of whom 1324 (19·3%) were diagnosed with CAPA. Diagnosis rates of CAPA ranged from 2·5% (14 of 566 patients) to 47·2% (58 of 123). We identified eight risk factors for CAPA. These factors included pre-existing comorbidities of chronic liver disease (odds ratio [OR] 2·70 [95% CI 1·21–6·04], p=0·02; I 2 =53%), haematological malignancies (OR 2·47 [1·27–4·83], p=0·008; I 2 =50%), chronic obstructive pulmonary disease (OR 2·00 [1·42–2·83], p<0·0001; I 2 =26%), and cerebrovascular disease (OR 1·31 [1·01–1·71], p=0·05; I 2 =46%). Use of invasive mechanical ventilation (OR 2·83; 95% CI 1·88–4·24; p<0·0001; I 2 =69%), use of renal replacement therapy (OR 2·26 [1·76–2·90], p<0·0001; I 2 =14%), treatment of COVID-19 with interleukin-6 inhibitors (OR 2·88 [1·52–5·43], p=0·001; I 2 =89%), and treatment of COVID-19 with corticosteroids (OR 1·88 [1·28–2·77], p=0·001; I 2 =66%) were also associated with CAPA. Patients with CAPA were typically older than those without CAPA (mean age 66·6 years [SD 3·6] vs 63·5 years [5·3]; mean difference 2·90 [1·48–4·33], p<0·0001; I 2 =86%). The duration of mechanical ventilation in patients with CAPA was longer than in those without CAPA (n=7 studies; mean duration 19·3 days [8·9] vs 13·5 days [6·8]; mean difference 5·53 days [1·30–9·77], p=0·01; I 2 =88%). In post-hoc analysis, patients with CAPA had higher all-cause mortality than those without CAPA (n=20 studies; OR 2·65 [2·04–3·45], p<0·0001; I 2 =51%). Interpretation The identified risk factors for CAPA could eventually be addressed with targeted antifungal prophylaxis in patients with severe COVID-19. Funding None.

Prevalence, Risk Factors, Treatment, Outcome, and Diagnosis of COVID-19-Associated Pulmonary Aspergillosis Using a Serum Galactomannan Assay

COVID-19 Associated Invasive Pulmonary Aspergillosis: Diagnostic and Therapeutic Challenges

COVID-19-associated pulmonary aspergillosis (CAPA): identification of Aspergillus species and determination of antifungal susceptibility profiles

Invasive Pulmonary Aspergillosis in Patients with SARS-CoV-2 Infection: A Systematic Review of the Literature

Clinical courses and outcomes of COVID-19 associated pulmonary aspergillosis in 168 patients with the SARS-CoV-2 omicron variant

Invasive pulmonary aspergillosis in the COVID‐19 era: An expected new entity

Clinical characteristics, bacterial coinfections and outcomes in COVID‐19‐associated pulmonary aspergillosis in a third‐level Mexican hospital during the COVID‐19 pre‐vaccination era

Clinical and Non-Clinical Characteristics of Pulmonary Aspergillosis in Non-Neutropenic Patients

Incidence, Risk Factors, and Outcomes of Patients with COVID‑19‑Associated Pulmonary Aspergillosis (CAPA) in Intensive Care Units: A Systematic Review and Meta-Analysis of 29 Cohort Studies

The Association Between COVID-19 and Invasive Pulmonary Aspergillosis: A Challenge for Health Care System

Risk factors for COVID-19 associated pulmonary aspergillosis and outcomes in patients with acute respiratory failure in a respiratory sub-intensive care unit

Incidence and outcomes of patients with COVID-19 associated pulmonary aspergillosis (CAPA) in intensive care units: a systematic review and meta-analysis of 31 cohort studies.

Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis

Investigation of risk factors for invasive pulmonary aspergillosis among patients with COVID-19

Incidence and inhospital outcomes of coronavirus disease 2019-associated pulmonary aspergillosis in the United States

Predicting COVID 19–Associated Pulmonary Aspergillosis Risk in Low- and Middle-Income Countries: A Matched Case-Control Study

Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patients

Complication of Intrapulmonary Cavitary Lesions after COVID-19 Finally Proved as Pulmonary Aspergillosis

COVID-19 associated Pulmonary Aspergillosis in Patients Admitted to the Intensive Care Unit: Impact of Antifungal Prophylaxis

Performance of the IMMY® sona Aspergillus lateral flow assay for the detection of galactomannan in tracheal aspirate samples from Brazilian patients with COVID-19-associated pulmonary aspergillosis: Cross-sectional and systematic review of literature

A Fatal Co-infections of Aspergillus latus and Pneumocystis jirovecii in COVID-19 Pneumonia Patient: Case Report